391 related articles for article (PubMed ID: 20063208)
1. Scleroderma lung disease.
Le Pavec J; Launay D; Mathai SC; Hassoun PM; Humbert M
Clin Rev Allergy Immunol; 2011 Apr; 40(2):104-16. PubMed ID: 20063208
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and management approaches for scleroderma lung disease.
Schoenfeld SR; Castelino FV
Ther Adv Respir Dis; 2017 Aug; 11(8):327-340. PubMed ID: 28621173
[TBL] [Abstract][Full Text] [Related]
3. Dyspnea due to pulmonary hypertension and interstitial lung disease in scleroderma: room for improvement in diagnosis and management.
Racz H; Mehta S
J Rheumatol; 2006 Sep; 33(9):1723-5. PubMed ID: 16960934
[No Abstract] [Full Text] [Related]
4. [Lung involvement in systemic sclerosis].
Posa M; Stelle M; Lador F; Chizzolini C
Rev Med Suisse; 2015 Apr; 11(469):802-6. PubMed ID: 26040160
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary arterial hypertension associated with systemic sclerosis.
Mathai SC; Hassoun PM
Expert Rev Respir Med; 2011 Apr; 5(2):267-79. PubMed ID: 21510736
[TBL] [Abstract][Full Text] [Related]
6. Imaging lung disease in systemic sclerosis.
Strollo D; Goldin J
Curr Rheumatol Rep; 2010 Apr; 12(2):156-61. PubMed ID: 20425026
[TBL] [Abstract][Full Text] [Related]
7. Assessment and management of scleroderma lung disease.
Bolster MB; Silver RM
Curr Opin Rheumatol; 1999 Nov; 11(6):508-13. PubMed ID: 10551676
[TBL] [Abstract][Full Text] [Related]
8. [Systemic sclerosis].
Legendre P; Mouthon L
Rev Prat; 2017 Sep; 67(7):775-783. PubMed ID: 30512777
[TBL] [Abstract][Full Text] [Related]
9. Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA.
Sankar S; Habib M; Jaafar S; Nagaraja V; Roofeh D; Young A; Huang S; Khanna D
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):43-51. PubMed ID: 33734968
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and risk factors for left ventricular diastolic dysfunction in a scleroderma cohort.
Vemulapalli S; Cohen L; Hsu V
Scand J Rheumatol; 2017 Jul; 46(4):281-287. PubMed ID: 27635465
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary hypertension in systemic sclerosis: different phenotypes.
Launay D; Sobanski V; Hachulla E; Humbert M
Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28954767
[TBL] [Abstract][Full Text] [Related]
12. Systemic sclerosis-associated interstitial lung disease.
Perelas A; Silver RM; Arrossi AV; Highland KB
Lancet Respir Med; 2020 Mar; 8(3):304-320. PubMed ID: 32113575
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.
Demir N; Şahin A; Küçükşahin O; Kayacan O; Dinçer İ; Sayın T; Karnak D; Turgay M
Heart Lung Circ; 2014 Jul; 23(7):667-73. PubMed ID: 24613044
[TBL] [Abstract][Full Text] [Related]
14. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
Mangat P; Conron M; Gabbay E; Proudman SM;
Intern Med J; 2010 Jul; 40(7):494-502. PubMed ID: 19460060
[TBL] [Abstract][Full Text] [Related]
15. [Epidemiological, clinical and evolutionary peculiarities of interstitial lung disease in systemic sclerosis].
Aydi Z; Rachdi I; Ben Dhaou B; Dridi M; Daoud F; Baili L; Boussema F
Rev Pneumol Clin; 2016 Apr; 72(2):122-8. PubMed ID: 26651932
[TBL] [Abstract][Full Text] [Related]
16. Desquamative interstitial pneumonia as the initial manifestation of systemic sclerosis.
Swartz JS; Chatterjee S; Parambil JG
J Clin Rheumatol; 2010 Sep; 16(6):284-6. PubMed ID: 20808169
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary hypertension phenotypes in patients with systemic sclerosis.
Haque A; Kiely DG; Kovacs G; Thompson AAR; Condliffe R
Eur Respir Rev; 2021 Sep; 30(161):. PubMed ID: 34407977
[TBL] [Abstract][Full Text] [Related]
18. Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis.
Valenzuela A; Nandagopal S; Steen VD; Chung L
Rheum Dis Clin North Am; 2015 Aug; 41(3):489-506. PubMed ID: 26210131
[TBL] [Abstract][Full Text] [Related]
19. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
20. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
